Clinical Trial

A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1, Randomized, Double-blind, Dose-Escalation, Placebo-Controlled, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to 64 Years
Trial Details
NCT Number NCT07728396
Lead Sponsor GC Biopharma Corp
Conditions COVID - 19
Enrollment 72 participants
Start Date 2026-01-28
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-27